Advertisement


Suzanne Trudel, MD, on Multiple Myeloma: Results From the DREAMM-8 Study of Treatments After Relapse

2024 ASCO Annual Meeting

Advertisement

Suzanne Trudel, MD, of Canada’s Princess Margaret Cancer Centre, discusses phase III findings showing that, in patients with relapsed or refractory multiple myeloma who had one or more prior lines of treatment, belantamab mafodotin-blmf plus pomalidomide and dexamethasone improved progression-free survival and showed a favorable overall survival trend compared with pomalidomide plus bortezomib and dexamethasone.



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
We've made a lot of progress for the treatment of myeloma. A lot of this comes from using triplets and quadruplet therapies in newly diagnosed patients with myeloma. We're incorporating the three main classes of anti-myeloma treatments, including proteasome inhibitors, the immunomodulatory drugs, and the anti-CD38 monoclonal antibodies. However, almost uniformly patients relapse and now there's an unmet need in those relapse patients because either the majority of them will be exposed and many will be refractory to the three main classes of drugs we use to treat myeloma. So we really need to look for new treatments that explore new drugs that have novel mechanisms of action. And this is where DREAMM-8 fits in. It tries to address that gap for the patients in first relapse. So DREAMM-8 was a randomized phase three study of belantamab mafodotin, which is an antibody drug conjugate that targets BCMA in combination with pomalidomide and dexamethasone, and it compared it to pomalidomide plus bortezomib and dexamethasone, specifically in patients who have relapsed after their first line of therapy that included lenalidomide. So a total of 302 patients were accrued to the study. 155 got randomized to the study arm, which was the belantamab mafodotin plus pomalidomide and dexamethasone, or we call it BPD or Bela-Pd. 147 got randomized, the control arm of pomalidomide plus bortezomib and dexamethasone. And the primary endpoint of the study was progression-free survival, but then we had other key secondary endpoints including overall survival, duration of response and MRD negativity rate. At a medium follow-up of 21.8 months the study met its primary endpoint of progression-free survival with progression-free survival not reached in the patients who were on the Bela-Pd arm and 12.7 months for the patients who received PVD. A 12 month PFS was 71% versus 51% for Bela-Pd versus PVD. And this really represents a clinically meaningful and statistically significant reduction, the risk of death by 48%. And we see from the Kaplan-Meier plots that the curbs separate early and remained sustained in favor of the Bela-Pd combination. We then also performed a subgroup analysis, and we see that the PFS benefit for belamaf was consistent across all the pre-specified subgroups. So this combination appears to benefit patients who have high risk disease, those patients who have relapsed after lenalidomide and our lenalidomide refractory, those that also are refractory to anti-CD38 monoclonal antibodies. So in addition to the progression-free survival benefit in favor of the belamaf-Pd, all the other secondary endpoints were also favoring the bela-Pd combination. This includes the rate of complete response, the MRD negativity rate at 10 to the minus 5 progression free survival too. And although the overall survival data is immature at this point in time, again overall survival favored belamaf plus Pd with a hazard ratio of 0.77. Now, when we look at the safety profile, essentially the toxicities that we observed were consistent with what we expect for the individual drugs in the combination. The most common adverse events were ocular toxicities, which are well described for MMAF containing ADCs, which is what belamaf is, and it's important to note with protocol pre-specified dose modifications, including dose interruptions and dose reduction there was a low discontinuation rate from the belamaf arm at 9%. The majority of ocular events were reversible with these modifications. So just in summary, really this represents a new treatment option for patients who have relapsed after one prior line of therapy and are lenalidomide exposed where there really is a gap in treatment at the present time with our currently available options.

Related Videos

Lymphoma

David J. Andorsky, MD, on DLBCL and FL: New Data on Use of Subcutaneous Epcoritamab

David J. Andorsky, MD, of the Sarah Cannon Research Institute and Rocky Mountain Cancer Centers, discusses EPCORE NHL-6, an ongoing study of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). As outpatients, the study participants were given subcutaneous epcoritamab-bysp to see whether they could be safely monitored and cytokine-release syndrome appropriately managed in the outpatient setting (Abstract 7029).

Prostate Cancer
Genomics/Genetics

Alicia Morgans, MD, MPH, and Susan Halabi, PhD, on Prostate Cancer: New Findings on Classifying Patients Into Risk Groups

Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Susan Halabi, PhD, of the Duke Cancer Institute and Duke University School of Medicine, discuss a clinical-genetic model that identified novel circulating tumor DNA alterations that are prognostic of overall survival and may help to classify patients with metastatic castration-resistant prostate cancer into risk groups useful for selecting trial participants (Abstract 5007).

Kidney Cancer

Brian I. Rini, MD, on Renal Cell Carcinoma: Exploratory Biomarker Results

Brian I. Rini, MD, of Vanderbilt Ingram Cancer Center, discusses phase III findings of the KEYNOTE-426 study of pembrolizumab plus axitinib vs sunitinib for patients with advanced renal cell carcinoma. He details the exploratory biomarker results, including RNA sequencing, whole-exome sequencing, and PD-L1 (Abstract 4505).

Skin Cancer

Christian U. Blank, MD, PhD, on Melanoma: Potentially Practice-Changing Results From the NADINA Trial

Christian U. Blank, MD, PhD, of the Netherlands Cancer Institute, discusses findings of an investigator-initiated phase III trial showing that neoadjuvant ipilimumab plus nivolumab followed by response-driven adjuvant treatment improved event-free survival in patients with macroscopic, resectable stage III melanoma compared with adjuvant nivolumab (LBA2)

Multiple Myeloma

Thierry Facon, MD, on Multiple Myeloma: Results From the IMROZ Study on Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone

Thierry Facon, MD, of the University of Lille and Lille University Hospital, discusses phase III findings showing for the first time that isatuximab, an anti-CD38 monoclonal antibody, when given with the standard of care (bortezomib, lenalidomide, dexamethasone, or VRd) to patients with newly diagnosed multiple myeloma who are transplant-ineligible, may reduce the risk of disease progression or death by 40.4% vs VRd alone (Abstract 7500).

Advertisement

Advertisement




Advertisement